Protection against doxorubicin-induced alopecia in rats by liposome-entrapped monoclonal antibodies.
Alopecia is a common side effect of several anti-cancer drugs, including doxorubicin. Based on our recent observation that a monoclonal antibody (MAD11) directed against this anthracycline inhibits the systemic toxic effect of the drug in mice, we investigated the possibility that MAD11 administered topically might protect against doxorubicin-induced alopecia. In 31 of 45 young rats treated intraperitoneally with doxorubicin, alopecia was completely prevented by topical treatment of the skin with liposome-incorporated anti-doxorubicin monoclonal antibody. This type of treatment might find relevance in preventing anthracycline-induced alopecia in cancer patients. Our findings also provide the first demonstration that liposome-entrapped monoclonal antibodies are capable of penetrating the stratum corneum of the skin without losing their function.
Balsari
A L
AL
Facoltà di Medicina, Universita di Milano, Italy.
Morelli
D
D
Ménard
S
S
Veronesi
U
U
Colnaghi
M I
MI
D000505:Alopecia / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D004317:Doxorubicin / Q000633:toxicity*; D004337:Drug Carriers; D005260:Female; D008081:Liposomes; D051381:Rats; D017207:Rats, Sprague-Dawley; D012867:Skin / Q000187:drug effects / Q000473:pathology
D000911:Antibodies, Monoclonal; D004337:Drug Carriers; D008081:Liposomes; D004317:Doxorubicin